» Articles » PMID: 35567733

Impact of Thymidine Phosphorylase and CD163 Expression on Prognosis in Stage II Colorectal Cancer

Overview
Specialty Oncology
Date 2022 May 14
PMID 35567733
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tumor-associated macrophages (TAM) are known to facilitate colorectal cancer (CRC) growth. High macrophage infiltration in thymidine phosphorylase (TYMP) expressing CRC may correspond to poor prognosis. The prognostic impact of the expression CD163, a receptor associated with TAM, and TYMP in stroma, respectively, tumor tissue is not yet established. The aim of this study was to identify the potential associations between TYMP and CD163 expression levels and relapse-free survival (RFS) of patients with stage II CRC, and if microdissection is of importance.

Methods: Stage II CRC patients, radically resected with relapse (n = 104), were matched to patients with a 5-year relapse-free follow-up (n = 206). Gene expression of TYMP and CD163 was analyzed in snap-frozen tumor tissues and in microdissected formalin-fixed tumor tissues separated into tumor epithelium and stroma.

Results: TYMP expression was high in poorly differentiated tumors, right-sided CRC, and tumors with high microsatellite instability CD163-expressing macrophages near tumor epithelial cells had high expression in poorly differentiated and T4 tumors. High TYMP expression in tumor epithelial cells was in the multivariate analyses associated with shorter relapse-free survival (hazard ratio 1.66; 95% confidence interval: 1.09-2.56; p < 0.05).

Conclusions: TYMP expression in tumor epithelial cells was associated with RFS and emphasizes the need for tissue microdissection. Additional studies are needed to establish whether TYMP and CD163 could add clinically relevant information to identify high-risk stage II patients that could benefit from adjuvant chemotherapy.

Citing Articles

Research progress of tumor-associated macrophages in immune checkpoint inhibitor tolerance in colorectal cancer.

Fan Q, Fu Z, Xu M, Lv F, Shi J, Zeng Q World J Gastrointest Oncol. 2024; 16(10):4064-4079.

PMID: 39473964 PMC: 11514660. DOI: 10.4251/wjgo.v16.i10.4064.


Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.

Kumari R, Syeda S, Shrivastava A Curr Med Chem. 2024; 31(32):5281-5304.

PMID: 38425113 DOI: 10.2174/0109298673282525240222050051.


EMR1/ADGRE1 Expression in Cancer Cells Upregulated by Tumor-Associated Macrophages Is Related to Poor Prognosis in Colorectal Cancer.

Akter R, Kim K, Kwon H, Kim Y, Eom Y, Cho H Biomedicines. 2022; 10(12).

PMID: 36551877 PMC: 9775542. DOI: 10.3390/biomedicines10123121.

References
1.
Zhong X, Chen B, Yang Z . The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression. Cell Physiol Biochem. 2018; 45(1):356-365. DOI: 10.1159/000486816. View

2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

3.
Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U . Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?. Virchows Arch. 2017; 472(4):519-531. DOI: 10.1007/s00428-017-2276-y. View

4.
Ding D, Yao Y, Yang C, Zhang S . Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer. Cancer Biomark. 2017; 21(3):689-700. DOI: 10.3233/CBM-170796. View

5.
Park J, McMillan D, Powell A, Richards C, Horgan P, Edwards J . Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin Cancer Res. 2014; 21(4):882-8. DOI: 10.1158/1078-0432.CCR-14-1686. View